Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET
Company Participants
Linda Marban – Chief Executive Officer
AJ Bergmann – Chief Financial Officer
Conference Call Participants
Joseph Pantginis – H.C. Wainwright
Leland Gershell – Oppenheimer
Aydin Huseynov – Ladenburg
Rick Miller – Cantor
Operator
Good afternoon, ladies and gentlemen, and welcome to the Capricor Therapeutics Second Quarter 2024 Earnings Call. At this time, all participant lines are in a listen-only mode. Following the presentation, we’ll conduct a question-and-answer session. [Operator Instructions] Also note that this call is being recorded on Wednesday, August 7, 2024.
And I would like to turn the call over to our CFO, AJ Bergmann for the forward-looking statements.
AJ Bergmann
Thank you. Good afternoon, everyone. Before we start, I would like to state that we will be making certain forward-looking statements during today’s presentation. These statements may include statements regarding, among other things, the efficacy, safety, and intended utilization of our product candidates, our future R&D plans, including our anticipated conduct and timing of preclinical and clinical studies, our enrollment of patients in our clinical studies, our plans to present or report additional data, our plans regarding regulatory filings, potential regulatory developments involving our product candidates, revenue and reimbursement estimates, manufacturing capabilities, potential milestone payments, our financial position and our possible uses of existing cash and investment resources.
These forward-looking statements are based on current information, assumptions and expectations that are subject to change and involve a number of risks and uncertainties that may cause the actual results to differ materially from those contained in the forward-looking statements.
These and other risks are described in our periodic filings made with the SEC, including our quarterly and annual reports. You are cautioned not to place undue reliance on these forward-looking statements, and we disclaim any obligation to update such statements.
With that, I’ll turn the call over to Linda Marban, CEO.
Linda Marban
Thanks, AJ. Good afternoon, and thank you for joining today’s second quarter conference call. Now over halfway through 2024, Capricor continues to make significant progress on bringing our lead asset, deramiocel, which was previously referred to as CAP-1002, closer to the submission of a Biologics License Application or BLA, for the treatment of Duchenne muscular dystrophy as well as developing our pipeline of exosome products for clinical development.
Our published results in June independently conducted clinical trials and the recent long-term open-label extension results, we believe are some of the strongest data seen in the space. As deramiocel addresses the inflammation and fibrosis caused by the cell death due to the lack of dystrophin, which typically protects muscle cells from damage.